CORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Corcept Therapeutics Inc (CORT) is not a strong buy for a beginner, long-term investor at this moment. The stock has faced significant challenges, including lawsuits, a recent price decline, and mixed analyst sentiment. While the company has some positive catalysts, such as strong gross margins and ongoing drug development, the negative catalysts, including legal issues, FDA delays, and declining EPS, outweigh the positives. Given the lack of strong trading signals and current technical weakness, it is better to hold off on investing in this stock for now.
The technical indicators suggest a bearish trend. The MACD is positive but contracting, RSI is neutral at 27.412, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 33.798, with resistance at 35.679. The stock has a 70% chance to decline slightly in the next week and month.
Gross margin increased to 98.74%, showing strong operational efficiency.
Positive Phase III trial data for relacorilant in ovarian cancer, with an FDA action date set for July 11,
Revenue increased by 11.12% YoY in Q4 2025.
Legal issues, including class action lawsuits alleging misleading statements.
FDA delays for relacorilant approval in Cushing's syndrome, requiring additional trials.
Declining EPS (-26.92% YoY) and net income (-21.00% YoY) in Q4
Recent price target downgrades by analysts, with some lowering expectations significantly.
In Q4 2025, revenue increased by 11.12% YoY to $202.13M, but net income dropped by 21.00% YoY to $24.29M. EPS also declined by 26.92% YoY to $0.19. Gross margin improved slightly to 98.74%, up 0.38% YoY.
Analyst sentiment is mixed. H.C. Wainwright and Canaccord maintain Buy ratings but have lowered price targets due to FDA delays and legal challenges. Wolfe Research downgraded the stock to Underperform with a $30 price target, citing significant risks and uncertainties.
